Health & Medicine Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health & Medicine Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allergies
Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
November 5th, 2007
Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, announced the initiation of a Phase I tolerance study of MRX-4 in 16 patients suffering from allergic rhinitis (AR). The randomized, placebo-controlled, double blind clinical trial is the first of two modules focusing on safety for Morria's first human study in AR. MRX-4 is nasally administered as a single dose either with or without an allergen challenge to determine tolerance. Results are expected by the end of the fourth quarter of 2007. "We are excited to be taking this significant step toward introducing a potentially safer,...
Source: Health & Medicine Week (2007-11-05)
|
